sellWeak cluster of 210b5-1 plan
N Anthony Coles sold $680k of CERE
director at Cerevel Therapeutics Holdings, Inc.. 27,176 shares at an average of $25.02, traded Nov 7, 2023, filed Nov 9, 2023.
Warning score
29Value
$680k
27,176 shares
Holdings after
2,704
-91% from before
From 52-week low
-
no price yet
From 52-week high
-
no price yet
Score components
- +15RoleDirector
- +21Trade size$680k at market
- +20Share of holdings soldSold 91% of holdings
- +8Cluster2 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Rows in this filing
Every transaction in Form 4 0000950170-23-062217, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Nov 7, 2023 | MOption exercise Common Stock10b5-1 | +27,076 | $3.50 | $95k | 29,780 | Nov 9, 2023 |
| Nov 7, 2023 | SOpen-market sale Common Stock10b5-1 | -27,076 | $25.02 | $678k | 2,704 | Nov 9, 2023 |
| Nov 8, 2023 | MOption exercise Common Stock10b5-1 | +100 | $3.50 | $350 | 2,804 | Nov 9, 2023 |
| Nov 8, 2023 | SOpen-market sale Common Stock10b5-1 | -100 | $25.16 | $2,516 | 2,704 | Nov 9, 2023 |
| Nov 7, 2023 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -27,076 | $0.00 | $0 | 2,525,341 | Nov 9, 2023 |
| Nov 8, 2023 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -100 | $0.00 | $0 | 2,525,241 | Nov 9, 2023 |
Related signals
Other insiders at Cerevel Therapeutics Holdings, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 25Weak | Cerevel Therapeutics Holdings, Inc. | N Anthony Coles director | $2.1M 50,000 shares | -76% | |
| 25Weak | Cerevel Therapeutics Holdings, Inc. | N Anthony Coles director | $2.1M 50,000 shares | -76% | |
| 23Weak | Cerevel Therapeutics Holdings, Inc. | N Anthony Coles director | $104k 2,506 shares | -14% | |
| 27Weak | Cerevel Therapeutics Holdings, Inc. | John Renger Chief Scientific Officer | $90k 2,161 shares | -25% | |
| 40Moderate | Cerevel Therapeutics Holdings, Inc. | N Anthony Coles director | $2.1M 50,000 shares | -95% | |
| 21Weak | Cerevel Therapeutics Holdings, Inc. | Ramiro Sanchez Chief Medical Officer | $425k 10,000 shares | -41% | |
| 35Weak | Cerevel Therapeutics Holdings, Inc. | Kenneth DiPietro Chief Human Resources Officer | $332k 8,000 shares | -24% | |
| 51Moderate | Cerevel Therapeutics Holdings, Inc. | Susan ALTSCHULLER Chief Financial Officer | $572k 13,808 shares | -45% | |
| 39Weak | Cerevel Therapeutics Holdings, Inc. | Scott Akamine Chief Legal Officer | $293k 7,072 shares | -49% | |
| 40Moderate | Cerevel Therapeutics Holdings, Inc. | Mark Bodenrader See Remarks | $327k 7,889 shares | -31% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.